The space renaissance newsletter: WE’RE ALMOST EIGHT BILLIONS: NOTHING CAN STOP US!
Why are governments useful in times of big crisis? Because they can recover the economy, printing currency, supporting stock markets after catastrophic events, such as pandemics.
U.S. Treasury Secretary Steven Mnuchin said he supports direct payments of $1,000 per adult and $500 per child to Americans within three weeks if Congress backs the plan.
“The president is determined that we are going to support” those affected, Mnuchin said in a Fox Business interview Thursday morning.
Cash handouts to all American households are gaining support in Congress as the best way to shore up an economy brought to a near-standstill by the coronavirus response.
:oooo.
A research team from ITMO University, with the help of colleagues from MIPT (Russia) and Politecnico di Torino (Italy), has predicted a novel type of topological quantum state of two photons. Scientists have also applied a new, affordable experimental method for testing this prediction. The method relies on an analogy: Instead of expensive experiments with quantum systems of two or more entangled photons, the researchers have used resonant electric circuits of higher dimensionality described by similar equations. The obtained results can be useful for the engineering of optical chips and quantum computers without the need for expensive experiments. The research was published in Nature Communications.
Light plays a key role in modern information technologies: With its help, information is transmitted over large distances via optical fibers. In the future, scientists anticipate the invention of optical chips and computers that process information with the help of photons—light quanta—instead of electrons, as it is done today. This will decrease energy consumption, while also increasing the capabilities of computers. However, to turn these predictions into reality, fundamental and applied research of light behavior at the micro- and nanoscale is needed.
In the new study, the researchers have theoretically predicted the formation of a new quantum state of photons: Two photons propagating in the array of quantum microresonators (qubits) can form a bound pair and settle down on the edge of the array. A proper experiment demands special nanostructures, as well as special devices to create such quantum state of photons and detect it. Currently, such capabilities are available only to very few research teams worldwide.
They’ll serve as the heart as “discovery factories” for planetary science, astrophysics, materials physics, fusion and more.
:oooo.
The new experiment demonstrated a bizarre quantum effect from the double-slit experiment at an unprecedented scale.
Looking for patient 1; Mr. Chen :
On Jan. 24, the Lancet, an independent medical journal, published a study showing Wuhan’s first patient was not connected to the seafood market. A joint research team representing China’s Xishuangbanna Tropical Botanical Garden, Huanan Agricultural College and the Chinese Institute for Brain Research have also said the seafood market is not the source of COVID-19.
https://www.upi.com/…/Reports-Chinas-first-C…/1201582811760/
CAMBRIDGE, Mass. and TARRYTOWN, N.Y., March 16, 2020 /PRNewswire/ — Sanofi and Regeneron Pharmaceuticals, Inc today announced they have started a clinical program evaluating Kevzara® (sarilumab) in patients hospitalized with severe COVID-19. Kevzara is a fully-human monoclonal antibody that inhibits the interleukin-6 (IL-6) pathway by binding and blocking the IL-6 receptor. IL-6 may play a role in driving the overactive inflammatory response in the lungs of patients who are severely or critically ill with COVID-19 infection. The role of IL-6 is supported by preliminary data from a single-arm study in China using another IL-6 receptor antibody.
This U.S.-based trial will begin at medical centers in New York, one of the epicenters of the U.S. COVID-19 outbreak, and will assess the safety and efficacy of adding Kevzara to usual supportive care, compared to supportive care plus placebo. The multi-center, double-blind, Phase 2/3 trial has an adaptive design with two parts and is anticipated to enroll up to 400 patients. The first part will recruit patients with severe COVID-19 infection across approximately 16 U.S. sites, and will evaluate the impact of Kevzara on fever and patients’ need for supplemental oxygen. The second, larger part of the trial will evaluate the improvement in longer-term outcomes including preventing death and reducing the need for mechanical ventilation, supplemental oxygen and/or hospitalization.
“At Sanofi, we are taking a leading role in addressing the global challenge of COVID-19 disease. Scientific evidence has emerged to suggest that Kevzara may be a potentially important treatment option for some patients, and this trial will provide the well-controlled, rigorous scientific data we need to determine if IL-6 inhibition with Kevzara is better than current supportive care alone. Additionally, we expect to rapidly initiate trials outside the U.S. in the coming weeks, including areas most affected by the pandemic such as Italy,” said John Reed, M.D., Ph.D., Sanofi’s Global Head of Research and Development. “In addition to Kevzara, Sanofi Pasteur, the vaccines global business unit of Sanofi, is leveraging previous development work for a SARS vaccine as part of our goal to quickly develop a COVID-19 vaccine.”
Have you ever gotten a whiff of a certain smell that brought you back to childhood? Or maybe a scent that reminded you of a past love affair?
A paper published in Learning and Memory reveals the power scents have to trigger memories of past experiences, as well as the possibility for odor to be used in treating memory-related disorders.
“If odor could be used to elicit the rich recollection of a memory — even of a traumatic experience — we could take advantage of that [therapeutically],” said Boston University neuroscientist Steve Ramirez, assistant professor of psychology and brain sciences and senior author of the study, in a statement.
